miR-21 is a Critical Therapeutic Target for Renal Fibrosis

Cell Biochemistry and Biophysics

Volumn 68, Issue 3, 2014, Pages 635-636

  He, Yong ^a   Huang, Cheng ^a   Li, Jun ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; MICRORNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ANIMAL; DIABETIC NEPHROPATHY; GENETICS; KIDNEY; LETTER; MALE; METABOLISM; PATHOLOGY;

ANIMALS; DIABETIC NEPHROPATHIES; KIDNEY; MALE; MATRIX METALLOPROTEINASE 9; MICRORNAS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84896031189     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-013-9745-y     Document Type: Letter

References (9)

1. Wang, J., Gao, Y., Ma, M., et al. (2013). Effect of miR-21 on renal fibrosis by regulating MMP-9 and TIMP1 in kk-ay diabetic nephropathy mice. Cell Biochemistry and Biophysics. doi: 10. 1007/s12013-013-9539-2.
2. Boor, P., Ostendorf, T., & Floege, J. (2010). Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nature Reviews Nephrology, 6, 643-656.
3. Zarjou, A., Yang, S., Abraham, E., et al. (2011). Identification of a microRNA signature in renal fibrosis: role of miR-21. American Journal of Physiology Renal Physiology, 301, F793-F801.
4. Zhong, X., Chung, A. C., Chen, H. Y., et al. (2011). Smad3-mediated upregulation of miR-21 promotes renal fibrosis. Journal of the American Society of Nephrology, 22, 1668-1681.
5. Glowacki, F., Savary, G., Gnemmi, V., et al. (2013). Increased circulating miR-21 levels are associated with kidney fibrosis. PLoS ONE, 8, e58014.
6. Kanwar, Y. S. (2012). TGF-beta and renal fibrosis: a Pandora's box of surprises. American Journal of Pathology, 181, 1147-1150.
7. Eddy, A. A. (2011). The TGF-beta route to renal fibrosis is not linear: the miR-21 viaduct. Journal of the American Society of Nephrology, 22, 1573-1575.
8. Chung, A. C., Dong, Y., Yang, W., et al. (2013). Smad7 suppresses renal fibrosis via altering expression of TGF-beta/Smad3-regulated microRNAs. Molecular Therapy, 21, 388-398.
9. Zhong, X., Chung, A. C., Chen, H. Y., et al. (2013). miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes. Diabetologia, 56, 663-674.